Among the different regimens, the highest occurrence rate of accompanying endocrinopathy was 28.1% (97/345) in patients on PD-1 inhibitor + CTLA-4 inhibitor treatment, followed by 23.8% (38/160) in patients on CTLA-4 inhibitors and 22.8% (132/578) in those on PD-1 inhibitors, and the lowest rate was 19% (19/97) in those on PD-L1 inhibitors. The gene discussed is CTLA4; the disease is endocrine system disorder.